Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 1
The Implementation Toolkit is: – High level roadmap of activities recommended to
support implementation of the Common Protocol Template (CPT) across project management, people, process & technology
– Templates and materials to communicate the initiative to various audiences
– Available to any Company or Sponsor who chooses to implement
.. but is not:– A detailed step-by-step workplan
– Activities that must be followed exactly, including Company or Sponsor-specific documentation
Objectives and Guiding Principles for the Implementation Leader
Guiding Principles– Each TransCelerate member company or non-member Sponsor is free to decide and must
decide for itself whether and in what manner to adopt any or all of the CPT components.
– This toolkit is intended to help those Companies or Sponsors who decide to adopt any CPT component to do so in the most efficient way possible.
– Implementation components are generic and may need to be tailored to a sponsor prior to use
– While TransCelerate member companies or non-member Sponsors have absolute discretion to implement TransCelerate solutions as they see fit, changing certain CPT tools will likely reduce some of the benefits associated with the tools.
– It is up to each TransCelerate member company or non-member Sponsor to define further the detailed steps for each implementation component within their respective organization.
The toolkit can be used in a highly flexible manner, as reflected in the guiding principles below.
i
<Audience and Date><Insert description of member company or sponsor audience for this presentation – e.g. senior leadership, group of stakeholders for doing impact assessment, participants authoring “pilot” trials, team members who will review and approve the protocol for “pilot” trials, broad audiences>
Common Protocol Template (CPT) Implementation Toolkit
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 3
TABLE OF CONTENTS
Introduction to TransCelerate
Common Protocol Template (CPT) Background
Model for the CPT
CPT Implementation Plan: Stakeholders, Advisors, and Company Plans
CPT Tools and Training for implementation
Other Tools to Support Implementation
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 4
What is TransCelerate?
Our visionTo improve the health of people around theworld by accelerating and simplifying the research and development of innovative new therapies.
Our missionTo collaborate across the global research and development community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high-quality delivery of new medicines.
TransCelerate is a not-for-profit entity created to drive collaboration across the pharmaceutical industry as a means to developing solutions for overcoming inefficiencies
Our core values Quality
Transparency & Openness to new ideas
Trust & Integrity
Collaboration
Courage
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 5
Engagement With the Wider Clinical Ecosystem Globally
Research
and
C
RO
Co
mm
un
ityIn
vestigative sites
Strategically focusing engagement efforts with selected key stakeholder groups – the intent is not to recreate, but partner whenever feasible
Reg
ula
tory
Bo
die
sIn
du
stry
Init
iati
ves
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 6
How Does TransCelerate Work?
Member Companies
WORKSTREAM
Define problem scopeShare best practicesDiscuss challengesCo-create solutions
Support & Resources (subject matter experts, time,
overhead)
Industry Solutions
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 7
14 TransCelerate Initiatives Chartered -
All initiatives are voluntary
Common Protocol Template6e-Consent1
4
Pediatric Trial Efficiencies 8Clinical Trial Diversification9Clinical Data Transparency1
0 Quality Management System11
*Original initiative which began in 2012
Model Approach for High-Quality, Risk-Based Monitoring*1Shared Site Qualification and Training*2Shared Investigator Platform*3Clinical Data Standards* (as a collaborator in CFAST)4Comparator Drugs for Clinical Trials*5 Placebo / Standard of Care1
2 e-Labels13Investigator Registry7
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 8
TransCelerate and CPT Workstream Membership
8
20 membercompanies in TransCelerat
e
17 member
companies
participate
in theCommonProtocol Templateworkstrea
m
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 9
Why a Common Protocol Template?
Heard at a recent DIA meeting…
“Patientrecruitmentischallengedbythe
complexityofprotocols.Sponsorsdothesame
thingstoo many different ways. Just make it the same!”
“Ifyouhavestandardswithouttraceability,thenyouaren'treally
CDISCcompliant.”
Investigator
FDA
“Justbecause‘subject’isintheregs,doesn’tmeanyou
havetouseit.Patientsthinkof‘subject’asaverb,andwho
wantstobesubjectedtosomething?Please use ‘trial
participant’ instead.”
PatientAdvocate
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 10
Problem Statement – Format and core content of study
protocols vary from sponsor to sponsor making interpretation difficult for study sites, IRBs, and regulators.
– Study protocols have become increasingly complex and lengthy driving up cost and time.
– Manual set-up of clinical systems based on non-standard “manual” protocols is time consuming, costly, and prone to error.
Solutions– Develop a model clinical trial
protocol, including format and core content, to ease interpretation and enable down-stream automation of many clinical processes.
– Develop model protocol endpoint definitions, incorporate into piloting of the template.
Background: Why a Common Protocol Template?
Guiding Principles– “Common” in a CPT: information always in the same place, means the same thing.
– Is it better? Move beyond incremental improvements and current limitations.
– It has to be better for everyone, but Investigators/Sites are the first priority.
– A human readable template that paves the way for an automated solution and facilitates the use of data standards.
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 11
End-User Stakeholders and Key “Must Haves” Define Scope and Solutions
PhysiciansClinical Scientists
Operations
RegulatorsData Scientists
Stats & Programming
Objectives Endpoints Methods Time & Events Supplies
Protocol Representation Models (CDISC)Data FlowsData StandardsProtocol ElementsConcepts
Investigators / SitesIRBs
Metadata
Traceability
Reuse
Automation
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 12
The Common Protocol Template Potentially Benefits Many Stakeholders
Sponsor
Sites
IRBPatient
Regulator
Operational efficiencies in creation of protocols
Reduction in redundancy in protocol content Enabling of therapeutic area standards Improved conduct of the study and quality
of data collected
Near Termand Potential Future State
Improved access to information with protocols streamlined and organized with an investigator focus
Increased consistency between sponsor protocols makes it easier when conducting multiple studies
Reduced need for additional documentation (e.g., study manuals)
Improved access to information with protocols streamlined
Increased consistency between sponsor protocols - easier review and faster approval
Improved communication from sites due to Increased consistency between protocols
Improved access to protocol information
Increased efficiency in clinical development, for participants & future patients
Reduction in complexity of regulatory reviews – easier reviews due to common structure and content
Increased ease of data interpretation Improved ability to compare protocols,
which improves quality of regulatory input on protocol design
Automation of downstream processes and reuse of content
Enabling of therapeutic area standards in additional TAs
Enabling collaborative clinical trials
• Opportunity for harmonization of additional documentation (e.g., study manuals)
• Enabling increased consistency of some case report forms
• Enabler for automation of IRBs submissions
Getting medicines faster, for participants & future patients
• Increased use of data standards, enabling end-to-end use of metadata and traceability
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 13
• A single, common protocol template structure with harmonized language
• Streamlined content enables identification of critical information for end users
• Begin working towards common endpoint definitions to align with Clinical Data Interchange Standards Consortium (CDISC) Therapeutic Area (TA) data standards. Asthma and Diabetes available in the first release.
• Reconnect processes (protocol, eCRF, development)
• Transformation of the design processo Analytics-driven trial design,
modelling, scenario planning
• Role-based access to protocol information (Principal Investigator [PI], Ethics, Participants)
• Connection to other systems
Common Protocol Template is Intended to Prepare for the Future State
Human- Readable Protocol
Human- Readable Protocol
IRB/IECsSites
Regulators
Foundation
Machine- Readable Protocol Metadata driven
processes
Content ReuseDisclosure
SAPCSR
eCRFStatistical Output
Future
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 14
The Model for the Common Protocol Template
LibrariesCore Protocol
Backbone
Common Level 1 & 2 Headings
Common text
Used across all phases
Focus on investigators
Healthy Volunteer
Patient
Asthma
Diabetes
AppendicesNon-study specific info, items
triggered by event
Implementation materialsinToolkit
Coreisstreamlined andfocusedonsite needs
ProposedAppendices toapplyasapplicable
Librariesgroupandstorecontentwhichisusedtopopulatethetemplate
Endpoint Definitionsdevelopedforasthmaanddiabetes
AsustainableGovernance Modeliscurrentlyindevelopment
Common Protocol Template and GuidanceGovernance Model
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 15
Template Development:Structure and Content
Structure – Level 1 and 2 Headings• Main focus -
Streamlined structure for logical flow
• Review of structure (Table of Contents) of member company templates
• Input from SCRS (Society for Clinical Research Sites) Site Advocacy Group
Section Content• Identification of common
wording in Core Backbone
• Review of GCP, ICH, and EU requirements
• Review of content from member company templates
Final CPT Structure and ContentFocus on sites (investigators and study staff) to have access to protocol information1. CPT Structure and Content will provide value to
Investigators, site staff, IRBs, regulators The same information is located in the same
place and means the same thing across Sponsors
Locked text (Level 1 and 2 Headings) is not to be modified or removed. “Not Applicable” is inserted if a section is not applicable.
2. Specific information to evaluate the ability to conduct a protocol, e.g. does the site have the patient population.
3. Refer to primary sources of information (e.g. Investigator Brochure) instead of duplicating information in the protocol
4. Model sections and text located in Appendices to be accessible, but will not impact the flow of the core protocol-specific information
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 16
Advisory Committee
eProtocol Advisory
Committee
Budapest Working Group (E3 & E6)
STAKEHOLDERFEEDBACK
“…to inform the development of a common human readable and electronic protocol template and
provide a forum for key stakeholders to inform future
direction and provide know-how
(Committee Charter)”
“EMA has not agreed to take up a position on the Advisory
Committee…..Happy to provide comments on any draft templates…”
OtherAdvisorsorInfluencers
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 17
Case Study: Member Company Pilot of TOC
The DRAFT CPT TOC (Level 1 and 2 headers) was used by a member company to author 3 protocols. There were no comments on the protocol TOC from the IRBs or the FDA or other Health Authorities for Trial 1 or 2 or 3. Several ex-US HA approvals are pending.
Trial
Type of Study
Phase
Indication
# of IRBs/EC Approved
FDA Review Approval
Ex-US Health Authority Review Submitted
ProtApproved to date by Ex-US HA
1 Oncology II Gastric 38 yes UK, Belgium, Canada, Czech Republic, Germany, Greece, Italy, Spain, Sweden, Turkey, Ukraine
All approved except Ukraine pending
2 Oncology II Gastric 43 yes Argentina, Australia France, Hungry, Poland, Romania, Russia, Slovakia, UK
All approved expect Argentina pending
3 Auto-immune
III Psoriasis 124 yes Argentina, Australia, Brazil, Canada, Czech Republic, Germany, Hungry, Japan, Mexico, Poland, Romania
All approved except Brazil pending
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 18
Ongoing CPT Maintenance/Governance: Business Continuity Plans
OngoingMaintenance&Governanceof
Template*
Collectandreportmetricsandfeedback
Updatestothetemplatesand
libraries
Governance Model being refined
Posted Template & Implementation Toolkit Member companies Public
• Metrics to monitor extent of adoption, regulator feedback
• Metrics to assess efficiencies gained
• Feedback collected via the TransCelerate website
• Update of the template and libraries as needed based on stakeholder feedback, regulatory guidance etc.
• Additional TA libraries
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 19
How will we go about adopting the CPT?
Options for Adoption of Common Protocol Template
TransCelerate Sponsor
Mapping Table Exercise forassessing the impact of CPT
Plan for Implementation at
_Sponsor_
Each Sponsor to tailor this slide.!
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 20
Options for Adoption of the Common Protocol Template
CPT Components
Companiesselectwhichtouse
TOC/Headingstructure
Commonlanguage
(core/appendices)
HealthyVolunteerLibrary
PatientLibrary
AsthmaLibrary
DiabetesLibrary
Companies and Sponsors choose their own path to adoption
• By phases• By use of libraries• By use of organization/structure and
content only (i.e., existing sponsor technology used, but headings/content adapted to mirror CPT)
Companies and Sponsors set their roll-out timeline
• Slowly introduce through pilots• Hard cut over date• Somewhere in between
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 21
Mapping Table Exercise to Assess Impact of CPT
Completing the Mapping Table Exercise will highlight the impacts and risks of adopting the CPT. Consider:
- Impact to sites/regulators- Sponsor responsibility for regulatory
compliance- Impact to internal sponsor processes and
documents downstream from protocol
Identify content used in a company sponsor template that is not included in the CPT
- Consider: Is this information found elsewhere (e.g., CTA, Monitoring Guidelines, Standard Operating Procedures, policy documents)?
Identify content in the CPT that is not currently in a company or sponsor template.
- Consider: Impact to adding this content?
Identify differences in wording of same topics in company or sponsor template vs CPT.
- Consider: Can company decide to accept CPT wording?
EXAMPLE
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 22
Mapping Tool:Results of Initial Impact Assessment
*Insert Company or Sponsor Specific Details*
Share results of Mapping Tool Exercise
Propose mitigation for content removed from template
Downstream impacts of content changes – distinguish between what needs to be mitigated for initial implementation vs longer term updates to SOPs
• Documents (SOPs, monitoring plans, agreements, etc.)
• Processes
Each Company or Sponsor to tailor this slide.
!
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 23
Proposed Implementation at____Sponsor ___
*Insert Company or Sponsor Specific Details*
Pilot with X trials
• Trials X, Y, Z
• Use template on desktop, not installed in authoring tool for initial implementation• Training/Orientation to template details
• Timing
• Assessment of results
Each Company or Sponsor to tailor this slide.
!
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 24
How to Use the Common Protocol Template
CPT Version 1.0 – Basic Word CPT Core Backbone and Libraries in
MSWord (.docx) Instructional text provided as red
hidden text available by toggling paragraph marks
Word doc, no installation needed (Open file and “Save As”)
Open on a workstation to author a protocolorUse for mapping exercise to compare sponsor template to CPT
Copyright ©2015 TransCelerate BioPharma Inc., All rights reserved. 25
What will be provided to support Implementation?
Tools What is it?
Introductory Video Short video providing an introduction to the template and the CPT Project
CPT Implementation Toolkit – Slide deck
This deck. Used for communication to various company or sponsor audiences – e.g. senior leadership, group of stakeholders for doing impact assessment, participants authoring “pilot” trials, team members who will review and approve the protocol for “pilot” trials, broad audiences for awareness.
Frequently Asked Questions (FAQs)
A summary of questions, and responses from the team, that various stakeholders may have about how the CPT was developed, how it will be implemented, and how it will be maintained.
Mapping Table Exercise; Mapping Table Instructions
A tool to compare the CPT to a company or sponsor protocol template. Allows identification, section by section, of differences in headings and content, and prompts team members to assess impact of implementation and possible mitigations needed.
Stakeholder Map A tool to assess the impact that implementing the CPT will have on each stakeholder group. Allows the Implementation Lead to plan for appropriate training and mitigation of concerns.
Text Color Guide Color coding used within the Common Protocol Template to distinguish common, suggested, example and instructional text. Paragraph marks must be visible in order for the instructional text to be displayed.
CPT Feedback Feedback can be submitted via the TransCelerate website http://www.transceleratebiopharmainc.com/
THANK YOU
Top Related